As researchers work to improve drug properties through drug design and molecular modeling, the line between drug delivery and drug substance will become more and more elusive in the near future, as shown in the analysis in this report. Consequently, in the next decade, drug delivery technologies will be a focal point of competition within the pharmaceutical industry and the needle-free drug delivery market will continue to grow rapidly.
This Kalorama Information report, Needle-Free Drug Delivery: The Market for Alternatives to Needle-Based Systems for Vaccines and Biologics, takes a look at this aspect of the pharmaceutical marketplace, with figures and forecasts for pharmaceutical companies and the companies that supply technology to them. The report discusses how the success of specific drugs will be tied to innovative delivery techniques, which will enable the targeting that will exploit the clinical properties of a new generation of drugs.
The development of better delivery systems in conjunction with the discovery of novel pharmacological compounds will lead to significant improvements in drug delivery. This report looks at that trend and provides current and forecasted revenues for the injectable drug delivery market, segmented into two main categories:
Needle-Free Products Market (Including Drug and Technology)
Needle-Free Products Market (Technology Only)
This breakout makes the report relevant to business plans of either device technology companies or pharmaceutical concerns. In addition, the following key information for business planners is included in the report:
Trends in the Vaccine Market
Market Size and Forecast for Needle-Free Vaccine Technology
Trends in Biopharmaceuticals
Leading Pharmaceutical Product Sold With Needle-Free Technologies
Products in Development
Detailed Profiles of Key Companies in Needle-Free Technologies
Current Market Size and Forecasts to 2016
Needle-Free Cost Savings, Autojets, Health Care Reform, and Other Trends and Developments
Companies Profiled in the report include:
Antares Pharma, Inc.
Bioject Medical Technologies, Inc.
MGI Pharma, Inc
Pacira Pharmaceuticals, Inc.
Baxter BioPharma Solutions
QLT USA, Inc
Ypsomed Holding AG
The findings in this report are based on both primary and secondary research. Kalorama conducted comprehensive research of secondary sources such as company literature, databases, investment reports, and medical and business journals. New technologies, market developments, and research and development trends and expenditures were identified through patent and database searches, as well as via interviews with key personnel. Person-to-person, email and telephone interviews were the primary method of gathering information.
All Kalorama reports advertise the single user price, which limits access to one user. We also feature department and global pricing for reports that will be utilized by more than one user at your company. Please ask your sales representative or select the correct license on our website.
For Kalorama's take on the healthcare news of the week, based on our analysis of healthcare markets, follow Kalorama Information's Key Point Blog at http://kaloramakeypoint.blogspot.com/
Innovations in Needle-Free Drug Delivery Driven by Complex New Therapeutics
Innovations in needle-free drug delivery will become a must as biological drugs become increasingly sophisticated and the traditional delivery methods are no longer suitable, according to Kalorama Information. The healthcare market research publisher estimates that needle-free drug delivery methods--which include patches, edible vaccines, pen injectors and more--will likely see a significant increase in revenues, with annual growth averaging 15.1% from 2011 through 2016 to reach $6.2 billion, according to their new report on these systems.
Drug delivery technology has come into its own in the last 25 years. Initially seen as merely a medium for a drug, it is now viewed as a tool for modifying the pharmacologic properties of drugs, improving methods of delivery, and targeting drugs to specific locations. Progress in the fields of microencapulation, polymer technology and nanoparticles now allow scientists to prolong the effect of drugs with short half-lives, and companies are developing a new generation of sophisticated delivery systems.
Arizona Biodesign Institute in Tempe is in the vanguard of the movement toward edible vaccines. The institute has concluded three early-stage clinical trials using potatoes bearing vaccines against hepatitis B, E. coli and the Norwalk Virus. Similarly, researchers at Japan's National Institute of Agrobiological Sciences continue to develop an edible vaccine produced in genetically modified rice.
"The line between drug delivery and drug substance will become increasingly elusive in the near future, as researchers work to improve drug properties through drug design and molecular modeling," notes Bruce Carlson, Kalorama Information's publisher. "In the next decade, drug delivery technologies will be a focal point of competition and the success of specific drugs will be tied to innovative delivery techniques, which will enable the targeting that will exploit the clinical properties of a new generation of drugs."
Competition in the segment has already increased over the past 10 years, with top delivery technology companies such as Antares, Bioject, MediImmune and Zogenix taking a leading role. Bioject offers several proprietary delivery technologies, including Biojector 2000, Cool.click, Injex, Serojet, and Vitajet, which are used in a wide range of applications including insulin, vaccine, and hormone drug delivery. Zogenix offers the Intraject system, which is a pre-filled, disposable, needle-free injector for the delivery of a wide range of liquid drugs, therapeutic proteins, and vaccines.